



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Texas Vaccine Providers Webinar

Tuesday, February 1, 2022

Disclaimer

The information presented today is based on CDC's recent guidance and MAY change.

Tuesday, February 1, 2022

COVID-19 Vaccine Discussion Topics

Opening Remarks – Tony Aragon, MS

COVID-19 Vaccine Updates – Saroj Rai, PhD, MPH

COVID-19 Vaccine Ordering Updates – Oscar Paz

Live Q&A

COVID-19 Vaccine VAOS Guidance – Michael Wrede

Live Q&A




Texas Department of State
Health Services

Opening Remarks

Tony Aragon, MS

Director | Immunization Unit

Percent of Total Population Vaccinated with an Additional/Booster by Age Group and Vaccination Date



	Population Estimates	People Vaccinated	Fully Vaccinated	Up-to-Date
Texas Total	28,995,881	20,017,959	16,918,868	8,704,719
		69%	58%	30%
5-11 years	2,898,962	791,629	492,119	492,119
		27%	17%	17%
5 years and older	26,967,586	20,013,084	16,917,568	8,704,459
		74%	63%	32%
12 years and older	24,068,624	19,221,455	16,425,449	8,212,680
		80%	68%	34%
18 years and older	21,596,071	17,507,830	15,051,247	7,659,538
		81%	70%	35%
65 years and older	3,734,229	3,522,878	3,130,286	2,082,627
		94%	84%	56%

People Vaccinated includes first doses of Moderna and Pfizer and single doses of Janssen.

Fully Vaccinated includes second doses of Moderna and Pfizer and single doses of Janssen.

Up-to-Date includes people with an additional/booster dose and people who are fully vaccinated but not yet eligible for an additional/booster Data as of 1/31/2022

Individuals Eligible for Booster

By Month – All Vaccines

Month Eligible Individuals Due Booster Dose (All COVID-19 Vaccines)	Individuals \geq 12 yrs (Total)	Individuals \geq 65 yrs
22-Jan	8,212,769	1,047,659
22-Feb	1,018,569	67,274
22-Mar	509,993	53,246
22-Apr	292,831	39,692
22-May	295,754	30,741
22-Jun	207,836	15,304
Total	10,537,752	1,253,916

Eligible population includes December 2020 to August 2021 for 2-dose vaccines and December 2020 to November 2021 for J&J vaccine. Individuals who received an additional dose after 8/13/21 are not included in the projection. As of 1/10/22, 2-dose vaccines are projected at 5 months and 2 months for J&J vaccine per ACIP recommendations.

Fully Vaccinated Individuals Eligible for Booster – All Vaccines

Age Group	2019 Texas Population	Total Eligible Individuals as of January Remaining Due for Booster*	Eligible Individuals Received an Additional/Booster Dose
Age 12-17 yrs	2,472,553	821,060	160,830
Age 18-64 yrs	17,861,842	6,344,050	3,850,497
Age \geq 65 yrs	3,734,229	1,047,659	1,876,370

Eligible population includes December 2020 to August 2021 for 2-dose vaccines and December 2020 to November 2021 for J&J vaccine. Individuals who received an additional dose after 8/13/21 are not included in the projection. As of 1/10/22, 2-dose vaccines are projected at 5 months and 2 months for J&J vaccine per ACIP recommendations.

COVID-19 Vaccine Updates

Saroj Rai, PhD, MPH

Senior Scientific Advisor | Office of the Chief State Epidemiologist

Moderna COVID-19 Vaccine

- On January 31, 2022, the FDA announced the second approval of a COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine, and will now be marketed as **Spikevax**, for the prevention of COVID-19 in individuals 18 years of age and older.
- Spikevax has the same formulation as the EUA Moderna COVID-19 Vaccine and is administered as a primary series of two doses, one month apart.
- Spikevax can be used interchangeably with the EUA Moderna COVID-19 Vaccine to provide the COVID-19 vaccination series.
- Moderna COVID-19 Vaccine is available under EUA as a two-dose primary series for individuals 18 years of age and older, as a third primary series dose for individuals 18 years of age and older who have been determined to have certain kinds of immunocompromise, and as a single booster dose for individuals 18 years of age and older at least five months after completing a primary series of the vaccine.
- The Moderna COVID-19 Vaccine is also authorized for use as a heterologous (or “mix and match”) single booster dose for individuals 18 years of age and older following completion of primary vaccination with a different available COVID-19 vaccine.
- The prescribing information for Spikevax can be found here: [Package Insert - SPIKEVAX \(fda.gov\)](https://www.fda.gov/oc/ohrt/moderna-covid-19-vaccine-spikevax)

COVID-19 Vaccine Administration Errors Guidance

For all vaccine administration errors:

1. Inform the recipient of the vaccine administration error.
2. Consult with the state immunization program and/ or immunization information system (IIS) to determine how the dose should be entered into the IIS, both as an administered dose and to account for inventory.
3. Providers are required to report all COVID-19 vaccine administration errors—even those not associated with an adverse event—to VAERS (<https://vaers.hhs.gov/>)
4. Determine how the error occurred and implement strategies to prevent it from happening again.

Type	Administration error/deviation	Do NOT repeat dose	Repeat dose <u>immediately</u>	Repeat dose after invalid dose by the <u>minimum interval</u> *	Contact manufacturer
Site/route	Incorrect site (i.e., site other than deltoid or anterolateral thigh)	✓			
	Incorrect route (i.e., route other than intramuscular)	✓			
Age	Administered to an unauthorized age group†	✓			

<https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-errors-deviations.pdf>

COVID-19 Vaccine

Administration Errors – Interim Recommendations

Appendix A. Vaccine administration errors and deviations

Table. Interim recommendations for COVID-19 vaccine administration errors and deviations

Type	Administration error/deviation	Interim recommendation
Site/route	<ul style="list-style-type: none"> Incorrect site (i.e., site other than the deltoid muscle or anterolateral thigh) 	<ul style="list-style-type: none"> Do not repeat dose.
	<ul style="list-style-type: none"> Incorrect route (e.g., subcutaneous) 	<ul style="list-style-type: none"> Do not repeat dose. Inform the recipient of the potential for local and systemic adverse events.
Age	<ul style="list-style-type: none"> Unauthorized age group 	<ul style="list-style-type: none"> If received dose at age less than 5 years, do not give another dose at this time.* If ages 5–11 years and: <ul style="list-style-type: none"> Moderna COVID-19 Vaccine administered as the first dose, administer a single dose of the age-appropriate Pfizer-BioNTech COVID-19 Vaccine at least 28 days after the Moderna COVID-19 Vaccine dose. Janssen COVID-19 Vaccine administered, because the efficacy of this vaccine in this age group has not been established, administer a single dose of the age-appropriate Pfizer-BioNTech COVID-19 Vaccine formulation at least 28 days after the Janssen COVID-19 Vaccine. If ages 12–17 years and: <ul style="list-style-type: none"> Moderna COVID-19 Vaccine administered as the first dose administer the age-appropriate Pfizer-BioNTech COVID-19 Vaccine formulation as the second dose at least 28 days after the Moderna vaccine dose. Should receive a booster dose at least 5 months later. Janssen COVID-19 Vaccine administered, because the efficacy of this vaccine in this age group has not been established, administer a single dose of the age-appropriate Pfizer-BioNTech COVID-19 Vaccine formulation at least 28 days after the Janssen COVID-19 Vaccine. Should receive a booster dose at least 5 months later.
Formulation and dosage	<ul style="list-style-type: none"> If ages 5–11 years and Pfizer-BioNTech COVID-19 Vaccine ≥12 years formulation (purple or gray cap) inadvertently administered 	<ul style="list-style-type: none"> If 0.1 mL administered, in general, do not repeat dose. However, based on clinical judgement (e.g., child received 2 doses of incorrect formulation), a repeat dose of Pfizer-BioNTech COVID-19 Vaccine 5–11 years formulation (orange cap) may be administered at an interval of 21 days after the dose given in error.

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html#Appendix-A

COVID-19 Vaccination Recommendations

January 7, 2022

	Primary Series			Booster Dose
	Dose 1	Dose 2	Dose 3 (Additional Dose) ^a (For Certain Immunocompromised Persons)	Single Booster Dose ^c
Pfizer (5-11 years) (orange cap)	0.2 mL <i>After dilution</i>	0.2 mL ^b @ 21 days after dose 1	0.2 mL ^b at least 28 days after dose 2	NO booster dose
Pfizer (≥12 years) (purple → gray cap)	0.3 mL <i>(Gray cap does not require diluent)</i>	0.3 mL @ 21 days after dose 1	0.3 mL at least 28 days after dose 2	0.3 mL ≥ 5 Months after dose 2 (primary series) or after additional dose ^a
Moderna (≥18 years)	0.5 mL	0.5 mL @ 28 Days after dose 1	0.5 mL at least 28 days after dose 2	0.25 mL ≥ 5 Months after dose 2 (primary series) or after additional dose ^a
J&J's Janssen (≥18 years)^d	0.5 mL	N/A	N/A	0.5 mL ≥ 2 Months after dose 1

a: Certain immunocompromised individuals only

b: Dose based on age at the time of the vaccination

c: Booster doses may be mix and match for individuals ≥18 yrs: [Booster dose may be mix-and-match vaccine](#)

d: [CDC preferentially recommends mRNA COVID-19 vaccines over Janssen COVID-19 vaccine](#)

Access the infographic at: <https://www.dshs.texas.gov/immunize/covid19/VaxRecAddBoosterDoses.pdf>

COVID-19 Vaccine Ordering Updates

Oscar Paz


Program Specialist V | Immunization Unit

Coming Soon: New VAOS Homepage

TVFC/ASN Vaccine Ordering Roll Out

VAOS users will see additional modules on the homepage when logging in, as we incorporate vaccine ordering for TVFC/ASN/Flu providers.

Though you will see the new modules, if you are not enrolled as a TVFC/ASN/Flu provider, you will not have access to them.




Providers can access [VAOS trainings guides](#) by selecting the **Updates and Resources** module.

Manufacturing Date vs. Expiration Date

Pfizer COVID-19 Orange Cap Vaccine

Pfizer COVID-19 orange cap vaccine formulation does NOT have an expiration printed on the vial. Instead, each vial has the lot number and date of manufacture printed on the label. **The date on the label is NOT the expiration date.**

 Expiry information for Ages 5 through 11 DILUTE BEFORE USE Orange Cap presentation and Ages 12 years and older DO NOT DILUTE Gray Cap presentation	
Printed Manufacturing Date	9-Month Expiry Date
06/2021	28-Feb-2022
07/2021	31-Mar-2022
08/2021	30-Apr-2022
09/2021	31-May-2022
10/2021	30-Jun-2022
11/2021	31-Jul-2022
12/2021	31-Aug-2022
01/2022	30-Sep-2022
02/2022	31-Oct-2022



This chart can be accessed here: https://www.cvdvaccine-us.com/images/pdf/Expiry_Document_January_2022.pdf


Manufacturing Date vs. Expiration Date

Pfizer COVID-19 Gray Cap Vaccine

Pfizer COVID-19 gray cap vaccine formulation does NOT have an expiration printed on the vial. Instead, each vial has the lot number and date of manufacture printed on the label. **The date on the label is NOT the expiration date.**

<u>Printed Manufacturing Date</u>	<u>9-Month Expiry Date</u>
06/2021	28-Feb-2022
07/2021	31-Mar-2022
08/2021	30-Apr-2022
09/2021	31-May-2022
10/2021	30-Jun-2022
11/2021	31-Jul-2022
12/2021	31-Aug-2022
01/2022	30-Sep-2022
02/2022	31-Oct-2022

This chart can be accessed on page 5 of the
Pfizer gray cap COVID-19 vaccine EUA: <https://www.fda.gov/media/153715/download>



Unable to Access VAOS?

Need help accessing VAOS?

Providers who need assistance **accessing VAOS** are encouraged to reach out to the **VacManagement** team using the contact information below:

Email: COVID19VacMgmt@dshs.Texas.gov

Phone: (833) 832-7068, option 2

Need help placing a COVID-19 vaccine order?

Providers who are temporarily locked out of VAOS and who need assistance **placing a COVID-19 vaccine order, confirming shipments, and reporting waste** should reach out to the **VacShipments** team using the contact information below:

Email: COVID19VacShipments@dshs.Texas.gov

Phone: (833) 832-7068, option 2

Live Q&A

COVID-19 Vaccine VAOS Guidance

Michael Wrede

COVID-19 Vaccine VAOS Guidance

- Placing a COVID-19 Vaccine Order Request and Confirming a Shipment
- Transferring COVID-19 Vaccine
- Reporting COVID-19 Vaccine Waste



Texas Department of State
Health Services

Placing a COVID-19 Vaccine Order Request and Confirming a Shipment



Enter Order Request Information

Field Title	Meaning
Post my info in the CDC Vaccine Finder	Select whether you want the CDC to direct the public to your facility for COVID-19 Vaccines.
Ancillary kit preference	Select between pediatric (PED) and adult (ADU) vaccination ancillary supply kits or select "No Ancillary Kit."
Who do you plan to vaccinate?	Select from the dropdown menu which populations of people you plan to vaccinate with these doses.
Do you accept walk ins?	Select from the dropdown menu whether your facility will vaccinate walk-in appointments.
Current quantity	Enter the number of doses of each type of vaccine you currently have on-hand.
Doses requested	Enter the number of doses you would like to order.
Certify ImmTrac2 reporting within 24 hours	Check this box to confirm that you agree to report administered doses to ImmTrac2 within 24 hours.
Specify additional beneficial details	For instance, specify the LTC facility you are requesting vaccines to serve.

New Service Request: COVID Order Request

COVID Order Request

* Facility

* Post my info in the CDC Vaccine Finder

* Ancillary kit preference

* Current quantity: Pfizer 100 (ages 5-11)

Current quantity: Pfizer 300 Doses

* Current quantity: Moderna 100 Doses

* Current quantity: Janssen 100 Doses

Certify ImmTrac reporting within 24 hrs ☐

Status
 Created

* Who you plan to vaccinate?

* Do you accept walk ins?

* Doses requested: Pfizer 100 (ages 5-11)

* Doses requested: Pfizer 300 Doses

* Doses requested: Moderna 100 Doses

* Doses requested: Janssen 100 Doses

Specify additional beneficial details

Cancel Save & New Save

Reminder: Enter number of **doses**,
NOT **vials**.

Pediatric COVID-19 Vaccine Ordering (Ages 5-11)

Note! Pfizer COVID-19 vaccine 100 dose packs are available only for pediatrics (Ages 5 - 11).

When ordering, please note the following:

- **Pediatric Ancillary Kits** or **("PED")** are only available for Pfizer 100 shipments.
- To order Pfizer COVID-19 vaccine 100 dose packs, you must select **"General Pediatric Population (Ages 5-11)"**.
- Input the number of **doses requested**.

New Service Request: COVID Order Request

COVID Order Request

* Facility
Search Accounts...

* Post my info in the CDC Vaccine Finder
--None--

* Ancillary kit preference
PED

* Current quantity: Pfizer 100 (ages 5-11)

Current quantity: Pfizer 300 Doses

* Current quantity: Moderna 100 Doses

* Current quantity: Janssen 100 Doses

Certify ImmTrac reporting within 24 hrs ☐

Status
Created

* Who you plan to vaccinate?
--None--

* Do you accept walk ins?
--None--

* Doses requested: Pfizer 100 (ages 5-11)

* Doses requested: Pfizer 300 Doses

* Doses requested: Moderna 100 Doses

* Doses requested: Janssen 100 Doses

Specify additional beneficial details

Cancel Save & New Save

* Who you plan to vaccinate?
--None--

Phase 1A - LTCF Residents

Phase 1B - 65+ or Medical Condition

Phase 1C - 50 to 64

School and child care personnel

General Adult Population

General Adolescent Population (Ages 12-17)

General Pediatric Population (Ages 5 - 11)

For more information on pediatric availability: [COVID-19 Vaccine Product Availability](#)

Confirming Shipments

What shipments do I need to confirm?

Only full pack size orders need to be confirmed. Providers DO NOT need to confirm **transfers** or **small pack size orders**.

Where do I confirm shipments?

Confirm shipments by navigating to the VAOS Accounts page and selecting the Vaccine Shipments tab.

When do I need to confirm shipments?

Providers must confirm shipments every time they receive a full pack size order before they administer the vaccine.

Who confirms shipments?

Primary or Backup Vaccine Coordinators must login to VAOS to confirm shipments.

VAOS Live Demo

Placing a COVID-19 Vaccine Order Request and Confirming a Shipment

Audience Poll

True or False: Providers are required to confirm shipments for **transfers** and **small dose orders** in VAOS.

- A. True
- B. False

Transferring COVID-19 Vaccine



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Coordinating Transfer of COVID-19 Vaccine

**As the *Transferring Provider*,
your role is to:**



Ship or physically transport vaccine



Maintain the cold chain



Cover any costs incurred in the transfer of vaccines




Include any ancillary supplies that were shipped with the original order

**As the *Receiving Provider*,
your role is to:**



Be prepared to receive and properly store the transfer



Work with the Transferring Provider to coordinate a shipment of 2nd doses (if needed), as *you will NOT automatically be shipped 2nd doses*








COVID-19 vaccines may only be transferred to an **approved COVID-19 Vaccine Provider**.



COVID-19 Vaccine Transfer Checklist


Preparing to Request a Transfer

Make sure you have the information on the right ready before beginning your vaccine transfer request.

Ensure You Have the Following:	
<input type="checkbox"/> Transferring Provider Information PIN and Receiving Provider Information PIN	
<input type="checkbox"/> CMO License Number	
<input type="checkbox"/> Reason for transfer	
<input type="checkbox"/> Vaccine type	
<input type="checkbox"/> Lot ID for the vaccine you want to transfer	
<input type="checkbox"/> Dose quantity to transfer	

Before submitting a request to transfer, you should coordinate with the *Receiving Provider* or facility so that you can submit their correct information – **including their Provider PIN.**

COVID-19 Vaccine Transfer Process



VAOS Live Demo

Transferring COVID-19 Vaccine

Audience Poll

True or False: Providers looking to transfer COVID-19 vaccine to another provider are required to initiate a COVID-19 vaccine transfer in VAOS *and* wait for the request to be approved before physically releasing the vaccine.

- A) True
- B) False

Reporting COVID-19 Vaccine Waste




TEXAS
Health and Human
Services

Texas Department of State
Health Services

Important Guidelines: Waste

FROM PROVIDERS...

If COVID-19 vaccines are wasted, providers need to report the waste in VAOS and then dispose of the vaccines.



TO THE CDC

DSHS then reports the waste from VAOS directly to the CDC on behalf of providers.

Waste reporting encourages careful handling and the use of every viable dose. It also helps the CDC identify potential problems in shipping and cold storage operations.

It is important for providers to prioritize vaccinating clients. If you have one person who wants to be vaccinated but you must prepare an entire vial to do so, you are encouraged to vaccinate the individual and attempt to not waste the rest of the vaccines if possible.

When to Report Waste

Waste should only be reported if a dose or vial goes bad **once it is within the provider's possession.**

Situation	Explanation
Expired vaccine	This is the date the vaccines expire and is set by the manufacturer. Ex: https://www.modernatx.com/covid19vaccine-eua/providers/vial-lookup
Mechanical failure	Ex: refrigerator loses power, causing vaccines to thaw.
Spoiled—other	Ex: patients don't show up to an appointment, but vaccines have already been thawed and cannot be refrozen.
Natural disaster/power outage	Ex: winter storm caused refrigerators to lose power.
Refrigerator too warm	Refrigerator temperature above EUA-listed optimal storage temperature.
Vaccine spoiled in transit	If the vaccine was spoiled before delivery to your facility , do not report it as waste. In this instance, contact McKesson and DSHS to arrange for replacement doses and report doses as spoiled when you confirm shipment in VAOS.
	If vaccines spoil as a result of a temperature excursion that resulted during a transfer , the receiving provider of the transfer reports the doses as waste.
	If vaccines spoil during or in transit to or from an off-site clinic , report the doses as waste.
Recall	The DSHS Immunization Unit would communicate necessary actions to impacted providers.

VAOS Live Demo

Reporting COVID-19 Vaccine Waste

Audience Poll

True or False: Reporting COVID-19 vaccine waste in VAOS is optional.

- A. True
- B. False


Live Q&A

Look for Our Follow-Up Email!

Monitor your inbox for a follow-up email communication that contains a **link to access today's webinar materials, links to register for future webinars, and a post-webinar survey where you can share your feedback!**

The email also contains **helpful resources for COVID-19 vaccine providers.**

The follow-up email will come from GovDelivery



This is where you can view today's (and past) webinars, as well as Highlights and the slides we presented.



Are You Receiving our Emails?

You may have unsubscribed from the service. If you would like to , re-subscribe, visit this

https://public.govdelivery.com/accounts/TXHHSC/subscriber/topics?qsp=CODE_RED.

Resources



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Billing Codes

For questions related to billing, visit the Centers for Medicare and Medicaid Services (CMS) resource, which includes CPT codes for COVID-19 vaccines.

CMS COVID-19 Vaccines and Monoclonal Antibodies:
<https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>

The screenshot shows the CMS.gov website. The header includes the CMS.gov logo, a search bar, and navigation links for Medicare, Medicaid/CHIP, Medicare-Medicaid Coordination, Private Insurance, Innovation Center, Regulations & Guidance, Research, Statistics, Data & Systems, and Outreach & Education. The breadcrumb trail reads: Home > Medicare > Medicare Part B Drug Average Sales Price > COVID-19 Vaccines and Monoclonal Antibodies. The left sidebar lists links for Medicare Part B Drug Average Sales Price files from 2007 to 2022, along with regulations and the current COVID-19 Vaccines and Monoclonal Antibodies page. The main content area is titled "COVID-19 Vaccines and Monoclonal Antibodies" and contains text about Medicare Part B payment for these products during the Public Health Emergency, a link to a toolkit, and a table of payment allowances and effective dates.

COVID-19 Vaccines and Monoclonal Antibodies

Medicare Part B Payment for COVID-19 Vaccines and Certain Monoclonal Antibodies during the Public Health Emergency

CMS has released a [set of toolkits](#) for providers, states and insurers to help the health care system prepare and assist in swiftly administering these products once they become available. These resources are designed to increase the number of providers that can administer the products and ensure adequate reimbursement for administration in Medicare, while making it clear to private insurers and Medicaid programs their responsibility to cover these products at no charge to beneficiaries. This webpage provides the payment allowances and other related information for these products. For more information, review the [COVID-19 provider toolkit](#).

Payment Allowances and Effective Dates for COVID-19 Vaccines and their Administration During the Public Health Emergency:(DOS = Date of Service, TBD = To Be Determined)

CPT Code or HCPCS Code	CPT or HCPCS Short Descriptor	Labeler Name	Vaccine/Procedure Name	National Payment Allowance Effective for Claims with DOS on or after 03/15/2021	National Payment Allowance Effective for Claims with DOS through 03/14/2021	Effective Dates
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	Pfizer-BioNTech Covid-19 Vaccine	\$0.010 ^[1]	\$0.010 ^[1]	12/11/2020 – TBD
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	Pfizer-BioNTech Covid-19 Vaccine Administration – First Dose	\$40.000 ^[2]	\$16.940 ^[2]	12/11/2020 – TBD

Ordering COVID-19 Vaccination Record Cards

COVID-19 Vaccine Providers can order additional vaccination record cards.

To order the COVID-19 vaccination record cards, email the following information in the format listed to the COVID-19 Vaccine Provider Help Desk at COVID19VacEnroll@dshs.texas.gov. Please note, **providers may not exceed 50 cards per request** and quantities ordered will be tracked by DSHS.

- *Quantity Requested*
- PIN:
- Name of facility:
- Point of contact name:
- Address line 1:
- Address line 2:
- City, State, Zip code:

For more information, refer to the email sent from DSHS via GovDelivery on 7/19/2021.

COVID-19 Vaccine Provider Support

Call the COVID-19 Provider Support Help Desk at 833-832-7068

Hours of Operation: Monday to Friday, 8 a.m. - 5 p.m. CT

Category	COVID-19 Vaccine Provider Enrollment (Syntropi)	COVID-19 Vaccine Provider Information and Safety Reporting	Vaccine Allocation & Ordering System (VAOS)	Vaccine Distribution & Shipments	Reporting for COVID-19 Vaccines
Sample questions	<ul style="list-style-type: none"> How to become a COVID-19 Vaccine Provider In-progress applications Update Enrollment accounts, including population numbers, email addresses, or primary/backup coordinators 	<ul style="list-style-type: none"> COVID-19 vaccine safety & medical info Administration of vaccine Reporting adverse events to VAERS Questions/concerns for clinical vaccine considerations 	<ul style="list-style-type: none"> Access to VAOS Question about completing a task or process in VAOS or dashboards Provider Webinars 	<ul style="list-style-type: none"> Tracking shipments Orders Vaccine transfer Waste disposal Changing inventory in VAOS 	<ul style="list-style-type: none"> Reporting to ImmTrac2 via online web application
Provider Support Channel	Provider Help Desk: (833) 832-7068 (Option 1) or (877) 835-7750 or Email: COVID19VacEnroll@dshs.texas.gov HealthCare Providers/Professionals https://www.cdc.gov/vaccines/hcp/index.html	COVID-19 Nurse Call Center: (833) 832-7068 (Option 4) or Texas 2-1-1 (Option 6), 8 a.m. to 5 p.m., Monday through Friday or Email: CoronaVirus@dshs.texas.gov General Immunization Questions: COVIDvaccineQs@dshs.Texas.gov	Covid-19 Vaccine Management: (833) 832-7068 (Option 2) or Email: COVID19VacMgmt@dshs.Texas.gov	Vaccine Shipments: (833) 832-7068 (Option 2) or Email: COVID19VacShipments@dshs.Texas.gov For questions about COVID-19 vaccine storage/handling, refer to the manufacturer resources .	ImmTrac2 team: (833) 832-7068 (Option 3) or (800) 348-9158, 8 a.m. to 4:30 p.m., Monday through Friday or Email: ImmTrac2@dshs.Texas.gov
Include in email:	Current and new vaccine coordinator name and email address (if new coordinators requested)		Provider name, org code, and primary and backup vaccine coordinator names and email addresses	Provider name, org code, and service request number or shipment number	

Vaccine Manufacturer Resources



Medical Information

Phone: 800-438-1985

Email:

PfizerMedicalInformation@pfizer.com

Website: www.PfizerMedInfo.com

Medical Team

Dr. Maria J. Tort

Cell: 832-240-6928

Email: maria.tort@pfizer.com



Medical Information

Phone: 866-663-3762

Email: MedInfo@modernatx.com

Medical Team

Pamela Gobina, PharmD, MBA

Cell: 215-360-5908

Temperature excursion related questions:

Email: excursions@modernatx.com



Medical Information

Phone: 800-565-4008

Medical Team

Dr. Nay Wei Soong

Cell: 504-554-4522

Email: nsoong@its.jnj.com

Temperature excursion related questions:

Email:

JSCCOVIDTEMPEXCURSION@its.jnj.com

Clinical Web Updates for Pfizer Gray Cap COVID-19 Vaccine

The following CDC webpages have been updated to include important information about the new Pfizer Gray Cap product. Below are links to the updated content:

Resource	Link
Questions about Single-Dose/Single-Use Vials	https://www.cdc.gov/injectionsafety/providers/provider_faqs_singlevials.html
Pfizer-BioNTech COVID-19 Vaccine Preparation and Administration Summary	https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/prep-and-admin-summary.pdf
Pfizer-BioNTech COVID-19 Vaccine Preparation Infographic	https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/diluent-poster.pdf
Pfizer-BioNTech COVID-19 Vaccine Questions CDC	https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/pfizer-bioNTech-faqs.html
Pfizer-BioNTech COVID-19 Vaccines CDC	https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html

Pfizer Medical Affairs-Led Training Events

Join Pfizer Vaccines US Medical Affairs for Medical Updates & Immunization Site Training for All Healthcare Providers.

Session topics include :

- Introduction of the **DO NOT DILUTE / Gray Cap** formulation for individuals 12 years of age and older.
- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
 - Ages 5 through 11 Years: **DILUTE BEFORE USE/Orange Cap**
 - Ages 12 Years and Older:
 - **DO NOT DILUTE/Gray Cap**
 - **DILUTE BEFORE USE/Purple Cap**
- Recent medical updates regarding the vaccine
- An overview of healthcare provider resources
- Question and answer session

These sessions will be **updated** to reflect new information and changes that evolve. Recent updates will be identified at the start of each session.

Date & Time	Password
Attendee link – Wednesday, February 02 - 12pm ET	j3Hrm53J8uG
Attendee link – Thursday, February 03 - 12pm ET	XxUF4Cg8Ma6
Attendee link – Tuesday, February 8 - 3pm ET	VggmmC9dZ33
Attendee link – Wednesday, February 9 - 12pm ET	xmPQNq7JJ32
Attendee link – Thursday, February 10 - 12pm ET	deMyFdVJ465
Attendee link – Tuesday, February 15 - 3pm ET	ZteZvrQ3M25
Attendee link – Wednesday, February 16 - 12pm ET	qhJNeDvr372
Attendee link -Thursday, February 17 - 12pm ET	niX7fg3xTR3
Attendee link – Tuesday, February 22 - 3pm ET	MMeBHKrM326
Attendee link – Wednesday, February 23 - 12pm ET	NgBarUWa228
Attendee link – Thursday, February 24 - 12pm ET	nMfj6BJEy32

Visit Pfizer's webpage for more information about Pfizer led training events:

<https://www.pfizermedicalinformation.com/en-us/medical-updates>

COVID-19 Vaccine Waste Guidance

Waste Disposal and Reporting Resources

While it is important to try to use every dose of vaccine possible, that should not be at the expense of missing an opportunity to vaccinate every eligible person when they are ready to get vaccinated.

The Texas Commission on Environmental Quality provides guidance on waste disposal:
<https://www.tceq.texas.gov/response/covid-19/waste-disposal-guidance>



For guidance on reporting Moderna doses wasted, see the following guide:
<https://www.dshs.texas.gov/immunize/covid19/Moderna-Wastage-Table-Texas.pdf>



For guidance on reporting waste in VAOS, see the following guide:
<https://www.dshs.texas.gov/immunize/covid19/Waste-in-VAOS.pdf>

COVID-19 Vaccine Waste
Reporting Waste and Generating Waste Reports in VAOS
October 25, 2021

For questions about reporting waste, call (833) 832-7068 (Option 2) or email COVID19VacShipments@dshs.Texas.gov.

COVID-19 Vaccine Product Availability Chart

The COVID-19 Vaccine Product Availability Chart below shows the vaccines available for ordering the Vaccine Allocation & Ordering System (VAOS). Please use the chart below to determine the number of doses you wish to order.

Moderna		Pfizer Adult/Adolescent (Gray Cap)		Pfizer Pediatric (5 -11 yrs)		Janssen/J&J
<100 Doses	>100 Doses	<300 Doses	>300 Doses	<100 Doses	>100 doses	>100 Doses
Place orders in multiples of 10 doses (1 vial) up to a maximum of 60 doses	Place orders in multiples of 100 doses	Place orders in multiples of 6 doses (1 vial) up to a maximum of 102 doses	Place orders in multiples of 300 doses	Place orders in multiples of 10 doses (1 vial) up to a maximum of 100 doses	Place orders in multiples of 100 doses	Place orders in multiples of 100 doses

Last Updated: 1/3/2022

COVID-19 VAOS Job Aids

In the [COVID-19 VAOS Job Aid Catalog](#) you can find all the DSHS job aids you may need as a COVID-19 vaccine provider.

Vaccine Allocation & Order System (VAOS) – Learning Resources

COVID-19 Vaccine Job Aids

- [VAOS Tips & Tricks](#) (11/2/2021)
- [COVID-19 Vaccine Data Dashboard](#) (6/29/2021)
- [COVID-19 Vaccine Product Availability](#) (10/28/2021)
- [COVID-19 Vaccine Order Requests in VAOS](#) (10/25/2021)
- [Vaccine Transfers in VAOS](#) (10/25/2021)
- [VAOS Quick Start Guide](#) (11/19/2021)
- [COVID-19 Vaccine Shipments](#) (10/25/2021)
- [Reporting Waste in VAOS](#) (10/25/2021)
- [Moderna Wastage Table](#) (11/2/2021)
- [Generating Reports in VAOS](#) (6/18/2021)

COVID-19 Therapeutics Job Aids

- [COVID-19 Therapeutics Job Aid](#) (9/24/2021)
- [Therapeutics Enrollment Guide](#) (11/10/2021)

VAOS E-Learnings

- [COVID-19 Vaccine & Therapeutics VAOS Videos](#)
- [TVFC/ASN VAOS Videos](#)

TVFC/ASN Job Aids

- [VAOS Quick Start Guide](#) (11/19/2021)
- [Open Ordering](#) (10/20/2021)
- [Uploading Temperature Logs](#) (10/18/2021)
- [Vaccine Shipments](#) (10/18/2021)
- [Vaccine Transfers](#) (10/18/2021)
- [Entering Doses Administered](#) (10/18/2021)
- [Reconciling Physical Inventory](#) (10/18/2021)
- [Reporting Waste](#) (10/18/2021)
- [Generating Reports](#) (10/18/2021)

Updated 11/10/2021

Disclaimer

The information presented today is based on CDC's recent guidance and MAY change.

Tuesday, February 1, 2022

Thank you!